Groundbreaking comparative study reveals best treatment for diabetes - Findings point to a paradigm shift in diabetes care, ...
Our FDA: Drug & Device Team examines the FDA’s new draft guidance that allows biosimilar developers to rely more on analytical and pharmacokinetic data, reducing the need for costly and time-consuming ...
Comparative effectiveness research has been the target of recurrent criticism in some political circles, with opponents claiming it’s the “gateway to rationing” or it encourages “cookbook medicine.” ...
The U.S. Food and Drug Administration (FDA) issued new draft guidance on October 29, 2025, proposing what it said were “major updates to simplify biosimilarity studies and reduce unnecessary clinical ...
Correspondence to Dr Parco M Siu, The University of Hong Kong, Hong Kong, 999077, Hong Kong; pmsiu{at}hku.hk Data sources Embase, MEDLINE, PsycINFO, Cochrane Library, Web of Science, Scopus and ...
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study We divided the borrowing ...
The Trump administration’s latest effort to lower drug costs is expanding to biosimilars, medications that are highly similar to biologic drugs made with or isolated from living organisms such as ...
Students majoring and minoring in CRES are prepared to enter the workforce as informed citizens in a diverse and challenging society.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results